Yale Cancer Center Presents Awards for Excellence in Clinical Care
The Yale Cancer Center Awards for Excellence in Clinical Care were presented by Kevin Billingsley, MD, MBA, FACS, to two outstanding physicians at Smilow Cancer Hospital: Manju Prasad, MD, MBBS, Professor of Pathology and Director of the Head & Neck and Endocrine Pathology Program and Saral Mehra, MD, MBA, FACS, Associate Professor of Surgery (Otolaryngology) and Section Chief, Head and Neck Surgery at the annual Yale Cancer Center Conclave on January 5, 2023.
Barbara Burtness, MD, Named Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital
Barbara Burtness, MD, Professor of Medicine (Medical Oncology), has been named Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital and Associate Cancer Center Director for Translational Research for Yale Cancer Center.
Berzosertib Plus Standard Chemoradiation Elicits Promising Responses in Locally Advanced HNSCC
Aarti Bhatia, MD, discusses the rationale for investigating berzosertib in this patient population, key updates from the phase 1 trial, and how these findings support the need for continued research of novel regimens in HNSCC.Source: OncLive
Press Release: Head and Neck Cancer Researchers Demonstrate the Capability of a Deep Learning Algorithm in the Post-Surgery Setting to Assess the Stage of Disease More Accurately Using Standard CT Scans
In a cohort of newly diagnosed patients in the E3311 trial at high risk for recurrence by standard assessment, a neural network algorithm demonstrated superior accuracy in measuring the extent of cancer spread, outperforming expert radiologistsSource: Ecog-Acrin
Judson Appointed Charles W. Ohse Professor of Surgery (Otolaryngology)
Benjamin Judson, MD, MBA, whose research interests include investigating outcomes and quality in head and neck cancer therapy, has been appointed Charles W. Ohse Professor of Surgery (Otolaryngology) at Yale School of Medicine, effective immediately.Source: YaleNews
Yale Doc: Throat, Neck Cancers Caused by HPV ‘Completely Preventable’ with Caccine
While cancer of the throat, back of the tongue, tonsils and soft palate (the location of the uvula), known as oropharyngeal cancer, can be caused by smoking or heavy drinking, HPV also has been linked to it, according to Dr. Saral Mehra, section chief for head and neck and otolaryngology surgery at the Yale School of Medicine.Source: CT Insider
The Quest to Eradicate HPV-Related Oropharyngeal Carcinoma: An Opportunity Not to Miss
Oropharyngeal squamous cell carcinoma (OPSCC) accounts for over half of all head and neck cancers. Since the 1970s, OPSCC has shifted from an environmentally triggered to virally mediated disease due to a sharp rise in human papillomavirus (HPV)-related SCC.Source: National Library of Medicine
Pembrolizumab With or Without Chemo Has Increased Efficacy With Increasing PD-L1 Expression in HNSCC
Pembrolizumab with or without chemotherapy resulted in a numerically longer overall survival benefit vs cetuximab plus chemotherapy in patients with head and neck squamous cell carcinoma and a PD-L1 combined positive score (CPS) between 1 and 19, but did not improve survival in the subset with a PD-L1 CPS of less than 1.Source: OncLive
Association of TP53 and CDKN2A Mutation Profile with Tumor Mutation Burden in Head and Neck Cancer
Head and neck squamous cell carcinoma (HNSCC) is a frequently devastating cancer that affects more than a half million people annually worldwide. In a paper recently published in AACR Journals, Dr. Barbara Burtness reveals the relation of the interaction of TP53 and CDKN2A mutations with elevated tumor mutation burden in HNSCC.Source: AACR Journals
Outcomes With Pembrolizumab, Pembrolizumab/Chemotherapy, and Cetuximab/Chemotherapy by PD-L1 CPS in Recurrent/Metastatic Head and Neck Cancer
In a post hoc analysis of the KEYNOTE-048 trial reported in the Journal of Clinical Oncology, Barbara Burtness, MD, and colleagues found that survival results with pembrolizumab and pembrolizumab/chemotherapy vs cetuximab/chemotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma and a PD-L1 combined positive score (CPS) of 1 to 19 supported CPS as a predictive factor for benefit of pembrolizumab and pembrolizumab/chemotherapy.Source: The ASCO Post
Manju Prasad, MD, MBBS, on Head and Neck Cancer Awareness Month
In recognition of Head and Neck Cancer Awareness Month, Manju Prasad, MD, MBBS, Professor of Pathology; Director, Endocrine Head and Neck Pathology Fellowship Program; Director, Endocrine Head and Neck Pathology, provides her insight.
Noxious Combination of Tobacco Smoke Nitrosamines with Bile, Deoxycholic Acid, Promotes Hypopharyngeal Squamous Cell Carcinoma, via NFκB, In Vivo
In vivo chronic exposure (12–14 weeks) of murine (C57Bl/6J) hypopharyngeal epithelium to tobacco smoke components (TSC) [N-nitrosamines; 4-(N-Methyl-N-Nitrosamino)-1-(3-pyridyl)-1-butanone (0.2 mmol/L), N-nitrosodiethylamine (0.004 mmol/L)], as the sole drinking fluid 5 days per week, along with topically applied (two times/day) bile [deoxycholic acid (0.28 mmol/L)], can accelerate TSC-induced neoplastic process, causing invasive carcinoma, enhancing NFκB activation and inducing a profound overexpression of Il6, Tnf, Stat3, Egfr, Wnt5a, composing an aggressive phenotype. Early assessment of bile components in refluxate of tobacco users can prevent the chronic silent progression of upper aerodigestive tract carcinogenesis. This in vivo model indicates that bile reflux might have an additive effect on the tobacco-smoke N-nitrosamines effect and could be suitable for large-scale studies of diagnostic and therapeutic interventions.Source: AACR
Efforts By Andrea Barbieri, MD, and Kristen Tupay Highlight Continuous Focus on Safety at Yale Pathology
Two recent efforts by Yale Pathology Department professionals highlight the continuous focus on patient and staff safety at Yale Pathology and within the Yale New Haven Hospital System (YNHHS).
Reduced Radiation Dose After Surgery May Improve Survival Rates in HPV-Related Throat Cancer
Transoral robotic surgery followed by low-dose radiation may reduce treatment intensity and improve long-term quality of life compared to usual care, which consists of high-dose radiation and chemotherapy, in patients with HPV-associated throat cancer, recent study findings demonstrate.Source: Cure Today